|Mutation Type||splice donor site (6 bp from exon)|
|Coordinate||94,377,609 bp (GRCm38)|
|Base Change||T ⇒ C (forward strand)|
|Gene Name||RAR-related orphan receptor gamma|
|Synonym(s)||Thor, thymus orphan receptor, RORgamma|
|Chromosomal Location||94,372,831-94,397,839 bp (+)|
|MGI Phenotype||Homozygotes for targeted null mutations exhibit lack of peripheral and mesenteric lymph nodes and Peyer's patches, reduced numbers of thymocytes, and increased apoptosis with loss of thymic expression of anti-apoptosic factor Bcl-xL.|
|Amino Acid Change|
|Institutional Source||Beutler Lab|
|Gene Model||predicted gene model for protein(s): [ENSMUSP00000143763] [ENSMUSP00000143610]|
|Predicted Effect||probably benign|
|Phenotypic Category||CD4+ T cells - decreased, CD8+ T cells - decreased|
|Alleles Listed at MGI|
|Mode of Inheritance||Autosomal Recessive|
|Local Stock||Live Mice, gDNA|
|Last Updated||2016-12-07 11:50 AM by Anne Murray|
|Record Created||2013-05-10 12:57 PM by Ming Zeng|
The chestnut phenotype was initially identified among G3 mice carrying mutations induced by N-ethyl-N-nitrosourea (ENU) and tested in the flow cytometric screen for deficiencies of peripheral blood cells. Chestnut mice exhibited deficiency in CD4+ and CD8+ T cells; other hematopoietic cell subsets were not significantly changed compared to the wild-type controls (Figure 1-3).
|Nature of Mutation|
Whole exome HiSeq sequencing of the G1 grandsire identified 80 mutations. Three G3 mice with the chestnut phenotype were genotyped at all 80 mutation sites and four mutations on chromosome 3 affecting Trpc3, Frem2, Gucy1b3, and Rorc were homozygous in all three of the chestnut mice. Subsequent analysis of five additional affected mice and 14 unaffected mice supported a causal relationship between the mutation in Rorc and the chestnut phenotype (LOD = 5.12); of the four mutations, only the Rorc mutation was homozygous in all eight affected mice. The mutation is a T to C transition at base pair 94,377,609 (v38) on chromosome 3 within the linear genomic DNA sequence of Rorc (GenBank genomic region NC_000069). The mutation affects the intron 1 donor splice site of the Rorc splice variant encoding Rorγt (GTAAGT-->GTAAGC; ENSMUST00000107292), but is not expected to affect the splice variant encoding Rorγ1.
RT-PCR and sequencing analysis were used to examine Rorγt splicing in chestnut tissues. Using primers spanning exons 1-3 (5’-GTGGAGCAGAGCTTAAACCCC-3’; 5’-CATCTCGGGACATGCCCAGAG-3’) (Figure 4A), RT-PCR of thymus and spleen mRNA showed that Rorγt expression was reduced in homozygous chestnut mice compared to wild-type mice (Figure 4B). Sequence analysis determined that the cDNA amplified from chestnut tissue was identical to the wild-type cDNA, indicating that the mutation does not completely abolish the function of the intron 1 donor splice site. It remains possible that a cryptic donor splice site in the 5’ UTR is used for splicing to the intron 1 acceptor splice site, but the resulting transcript degraded by the nonsense mediated decay pathway. Possible partial or complete retention of intron 1 in the spliced mRNA was not tested. Reduced expression of Rorγt may account for the observed phenotype.
RAR-related orphan receptor gamma (RORγ) is a member of the RAR-related orphan nuclear hormone receptor transcription factor family that includes RORα and RORβ (see the record for 4-limb clasper for information about RORβ). Nuclear hormone receptors, including the ROR proteins, are structurally similar and each has an N-terminal domain (A/B region), a DNA-binding domain (DBD), a hinge domain, and a C-terminal ligand-binding domain (LBD) [Figure 5; reviewed in (1)]. The ROR proteins are highly conserved: the DBDs are approximately 90% identical and LBDs are 48% and 46% identical, respectively, between RORγ and RORα or RORβ [(2); reviewed in (3)]. The ROR proteins generally bind as monomers to retinoic acid-related orphan receptor response elements (ROREs; AGGTCA immediately preceded by a 6-bp A/T-rich region) in target genes. Once bound to ROREs, RORs constitutively recruit coactivators to activate transcription (2;4-6). For more information about these domains, please see the record for 4-limb clasper.
Few endogenous ligands have been described for RORγ. However, structural analyses provided evidence that 7-oxygenated sterols (e.g., 7-α-hydroxycholesterol, an intermediate in bile acid metabolism) may be natural ligands for both RORα and RORγ through binding to their LBDs (7). The LBD of human RORγ in complex with the second LxxLL motif of nuclear receptor coactivator 2 (NCOA2; alternatively, SRC2) and several hydroxycholesterol (HC) ligands (20α-HC, 22R-HC, and 25-HC) has been crystallized [Figure 6; PDB:3KYT; (8)]. The RORγ LBD is comprised of 12 α-helices and two short β-strands folded into a three-layer helix sandwich, similar to other ROR LBDs (8). The three RORγ LBD-HC structures were similar overall and the HCs adopted the same position in the ligand-binding pocket (8). The HC ligands were enclosed within the bottom half of the LBD and were oriented with the hydroxyl tail toward helix H11 of the LBD and the A ring toward helices H1 and H2 (8). RORγ interacts with the coactivator SRC2 via a charge clamp pocket formed by residues from the activation function (AF-2) motif at the C-terminal end of the LBD and helices H3, H4, and H5 (8).
Rorc generates two isoforms of RORγ, RORγ1 and RORγt (alternatively, RORγ2), by the use of alternative promoters and/or by alternative splicing of a common pre-mRNA (9-13). The RORγ isoforms have the same DBDs and LBDs, but RORγt lacks the N-terminal 24 amino acids of RORγ1 encoded by the first two exons of Rorc and has three alternative residues encoded by the first exon specific to RORγt [Figure 5; (9;13); reviewed in (3;14;15)].
The chestnut mutation is predicted to weaken the intron 1 donor splice site, resulting in retention of all or a portion of intron 1, and/or skipping of exon 1 in the processed RORγt mRNA. It is unknown whether a non-functional protein is translated, or if the mutant transcript is subject to nonsense mediated decay. Only the RORγt isoform is predicted to be affected by the chestnut mutation.
RORγ1 and RORγt have different tissue expression patterns [reviewed in (14)]. RORγ1 is expressed in several tissues including liver, kidney, small intestine, brain, brown adipose tissue, skeletal muscle, pancreas, prostate, testis, and thymus (6;10;11). Mongrain et al. detected low levels of RORγ1 in all thymocyte subsets (16). RORγ1 exhibits an oscillatory expression pattern in the liver, thymus, brown adipose tissue, kidney, and small intestine; expression in the muscle and testis is constant (16;17). Examination of several Zeitgeber time- points determined that peak expression of RORγ1 was around Zeitgeber time 16; Zeitgeber time is a standard of time based on the period of a synchronizing agent (16-19). Oscillation of RORγ1 expression is proposed to be mediated by Clock/Bmal1 heterodimers that bind one of the E-boxes (E2) of Rorc (16;17).
RORγt is highly expressed in the thymus, with expression restricted to double-positive (DP; CD4+CD8+) thymocytes (6;9;11;13;20). RORγt is downregulated during positive selection and turned off in mature single-positive (SP) thymocytes and peripheral T cells (9;21). RORγt is also expressed in fetal lymphoid tissue inducer cells [LTi; LTi function in the development of lymph nodes and Peyer’s patches; (9;12;20;22)], IL-17-producing cells [e.g., Th17 cells and γδ T cells (23-25)], NKp46+ NK cells (26;27), and thymic epithelial cells (16). During early embryogenesis RORγt expression by LTi cells has been observed in the spleen (20), but expression was not detectable in the adult spleen (28). Using quantitative PCR with primers specific for the RORγt isoform, Mongrain et al. determined that RORγt mRNA is expressed at very low levels in muscle, testis, and liver (16). They speculate that the differences observed in their findings compared to previous studies are due to the sensitivity of the methods used in their study (16). The function of RORγt in non-immune tissues is unknown and was not speculated (16).
The proteins of the nuclear receptor superfamily are DNA-binding proteins that regulate gene expression in response to physiological, metabolic, and nutritional signals such as steroids, retinoids, thyroid hormones, and vitamin D3 [(29); reviewed in (30)]. In doing so, the nuclear receptors regulate cell differentiation, organ physiology, and development. The three members of the ROR family, RORα, RORβ, and RORγ, and their isoforms display distinct tissue expression patterns and thus control the development and function of specific cellular subsets. The function(s) of RORγ1 and RORγt are discussed, below. Findings based on analysis of mice or cells expressing a null allele of Rorc may implicate either or both RORγ1 and RORγt; the general name “RORγ” is used in these cases to indicate this possibility.
RORγt in thymocyte differentiation/maturation
One function of RORγ during thymopoiesis is to negatively regulate DP thymocyte apoptosis to promote cell survival [Figure 7; (31;32); reviewed in (14)]. Thymocytes are greatly reduced in RORγ-null (Rorc-/-; MGI: 2386114; (31;32) and RORγt-deficient mice [MGI:3026635; (12)]. In particular, loss of RORγ expression led to a loss of CD4+CD8+ double positive (DP) as well as CD4+ and CD8+ single positive (SP) thymocytes because of a block in thymocyte development from the immature single positive (CD4-CD8lowCD3-) stage to the DP stage (31;32). RORγt promotes thymocyte survival by activating a program of gene expression that depends on recruitment of the SRC family of transcriptional coactivators (e.g., SRC1 and GRIP1) to the AF2 domain of RORγt [(31-33); reviewed in (28)]. In addition, RORγt positively regulates the expression of the anti-apoptotic protein Bcl-xL, a known regulator of thymocyte survival (34). Thus, DP thymocytes in Rorc-/- mice express greatly reduced levels of Bcl-xL and the RORγ deficient DP thymocytes had a shorter lifespan than wild type DP thymocytes (31;32). Wang et al. identified the β-catenin/T cell factor 1 (TCF-1) pathway as upstream of RORγt in Bcl-xL-mediated DP thymocyte survival regulation (35). DP thymocytes in Rorc-/- mice express lower levels of TCR than those found in normal mice because RORγ regulates TCRα repertoire formation and TCRα gene rearrangement by binding to the T early α (TEA) promoter, a transcription factor that regulates TCRα recombination [(13;31;36;37); reviewed in (3;14)]. In addition to binding to TEA, RORγ also positively regulates Bcl-xL expression, subsequently regulating the TCRα repertoire. In Rorc-/- mice, the 3’ Jα usage was impairedand that Jα usage was skewed to the 5’ end of the locus; the 3’ Jα usage could be corrected upon expression of a Bcl-xL transgene [(36); reviewed in (14)]. Furthermore expression of transgenic Bcl-xL skewed Jα usage to the very 3’ end of the locus and induced a 3’ Jα bias to the peripheral TCRα repertoire in wild-type and Rorc-/- mice (36). RORγ may also facilitate TCR surface expression later in thymocyte development, but this has not been definitively proven [reviewed in (28)].
RORγ inhibits expression of Fas ligand (FasL) and interleukin-2 (IL-2), protecting hybridomas from TCR-induced apoptosis [(9;38); reviewed in (14)]. During TCR-induced apoptosis and thymocyte development RORγ inhibits nuclear factor of activated T cells (NFAT) by competing for DNA binding sites, subsequently inhibiting NFAT-regulated transcription; NFAT is a factor that stimulates the transcriptional activation of both FasL and IL-2 (38;39). However, deregulated expression of FasL does not play a role in promoting apoptosis in Rorc-/- DP thymocytes because mutation of Fasl in Rorc-/- mice fails to rescue cell death. In addition, RORγt negatively regulates the transcription of c-Rel, another regulator of IL-2 expression (21;40).
Following antigen activation, CD4+ T cells differentiate into several types of effector and regulatory T (Treg) cells [Figure 7; reviewed in (41)]. Interleukin-17 (IL-17)-producing helper T (TH17) cells are particularly important mediators of host defense against extracellular bacterial pathogens at mucosal barriers in the intestine and airways. However, in excess they contribute to the development of many autoimmune diseases (e.g., systemic lupus erythematosus, multiple sclerosis, inflammatory colitis, rheumatoid arthritis and psoriasis) by secreting several pro-inflammatory cytokines and chemokines including IL-17A, IL-17F, IL-21, IL-22, TNF, and IL-6 as well as opposing the function of Treg cells [(42;43); reviewed in (41;44)]; immune homeostasis is maintained by balancing the levels of TH17 and Treg cells [reviewed in (41)]. RORγt and RORα promote TGF-β plus IL-6- or IL-21-induced TH17 differentiation and suppress TNF- and IL-1β-induced TH1 and TH2 differentiation (45-50). Signal transducer and activator of transcription 3 (STAT3) and runt-related transcription factor 1 (RUNX1) collaborate with RORγt and RORα to induce expression of Il17a and Il17f, subsequently promoting TH17 differentiation and cytokine expression (48;51-53). RORγt can also activate the gene that encodes IL-23R (the receptor for IL-23) as well as promote the surface expression of the TH17 chemokine receptor CCR6 (23;49;50;52). HIF1α has emerged as a regulator of Rorc transcription that can also bind to RORγt to promote the transcription of RORγt target genes and TH17 differentiation (25;54). HIF1α also can negatively regulate Foxp3 expression posttranslationally (25). Foxp3 suppresses TH17 cell differentiation by directly binding to RORγt and blocking its ability to activate Il17a and Il17f transcription; Foxp3 can also interact with and inhibit Runx1 (55).
Development of secondary lymphoid organs
Rorc-/- mice do not have lymph nodes (both peripheral and mesenteric) as well as Peyer’s patches due to the absence of lymphoid tissue inducer (LTi) cells, which require RORγt for their generation and survival through the regulation of Bcl-xL (12;31;32;56). Studies have shown conflicting results on the splenic structure of Rorc-/- mice (MGI:2384142). Sun et al. reported no change in splenic structure (31), while Zhang et al. reported enlarged spleens due to an accumulation of conventional resting B cells; B lymphocyte development in the bone marrow and spleen in the Rorc-/- mice were normal and B cell levels in the blood were comparable to controls (56).
Other functions of RORγ
Members of the ROR family, including RORγ1, are involved in the regulation of circadian behavior, likely by coupling the action of circadian-regulatory genes with ROR-controlled metabolic genes (4;16;19). ROR proteins exhibit oscillatory expression patterns in specific tissues. In particular, RORγ1 expression follows a circadian oscillation in liver, brown adipose tissue, and kidney, where it is expressed at low levels during the day and higher levels at night (16;19). RORγ1 positively regulates the expression of Bmal1, a circadian clock gene, in liver and muscle (but not testis) (16). RORγ1 has also been shown to regulate the level of expression of other circadian clock genes including Cry1, Rev-Erbα, Per2 and E4bp4 in liver, brown adipose tissue, kidney, and small intestine (19). Microarray analysis of gene expression in RORα- or RORγ-deficient liver demonstrated that RORα and RORγ regulate the expression of numerous genes encoding metabolic enzymes (57). In several tissues (liver and brown adipose tissue), RORγ and RORα had redundant functions in their regulation of clock and metabolic genes (19;57).
During adipocyte differentiation, RORγ mRNA and protein expression is high in confluent 3T3-L1 preadipocytes; RORγ is reduced upon the induction of differentiation (58). RORγ has been identified as a factor that negatively regulates adipocyte differentiation at the initial steps of adipogenesis by repressing the early adipogenic gene Mmp3 (58). In addition, mutations in RORC have been linked to fat accumulation in cattle (59). In 3T3-L1 preadipocytes, induction of differentiation to adipocytes results in a decline in both the mRNA and protein levels of RORγ1 (58). In late stages of D1 and 3T3-L1 cell differentiation, RORC expression is upregulated (60). In cells overexpressing RORγ, adipogenic proteins such as C/ebpα, C/ebpβ, C/ebpδ and Pparγ were decreased; adipogenic genes c-Jun, c-Fos and A-Fabp were also repressed (58).
Chestnut mice exhibit deficiencies of both CD4+ and CD8+ T cells, similar to Rorc-/- [MGI: 2386114; (19;33) and MGI: 2384142; (35)] and RORγt-deficient mice [MGI:3026635; (12)]. Reduction in SP thymocytes is due to a block in thymocyte development from the immature single positive stage to the DP stage, as well as increased apoptosis of the DP thymocytes (19;33;35;38). A consequence of increased thymocyte cell death related to reduced Bcl-xL expression appears to be impaired TCRα rearrangement (14).
chestnut(F):5'- TGCCTGTCATCATACCCAATGCAC -3'
chestnut(R):5'- ACCATTGCTGCCAAGGAAGCTG -3'
chestnut_seq(F):5'- CTGTGTGGAGCAGAGCTTAAAC -3'
chestnut_seq(R):5'- CCAAGGAAGCTGCCAGG -3'
Chestnut genotyping is performed by amplifying the region containing the mutation using PCR, followed by sequencing of the amplified region to detect the single nucleotide transition. The same primers are used for PCR amplification and for sequencing.
Chestnut(F): 5’- TGCCTGTCATCATACCCAATGCAC -3’
Chestnut(R): 5’- ACCATTGCTGCCAAGGAAGCTG -3’
Chestnut_seq(F): 5’- CTGTGTGGAGCAGAGCTTAAAC -3’
1) 94°C 2:00
2) 94°C 0:30
3) 55°C 0:30
4) 72°C 1:00
5) repeat steps (2-4) 40X
6) 72°C 10:00
7) 4°C ∞
The following sequence of 427 nucleotides (from Genbank genomic region NC_000069 for linear DNA sequence of Rorc) is amplified:
4547 tgcc tgtcatcata 4561 cccaatgcac ctctgggggt tggggggctg tcacttggcc acctgtgtgg agcagagctt 4621 aaacccccct gcccagaaac actgggggag agctttgtgc agatctaagg gctgaggcac 4681 ccgctgagag ggcttcaccc cacctccact gccagctgtg tgctgtcctg ggctacccta 4741 ctgaggagga cagggagcca agttctcagt catgagaagt aagtgaatgg gggcatccgg 4801 tcatggggga gcctgggtcc tgtcaccatt cctaggcccg ctgaatagga gtgtatcttg 4861 gaaaccgtgc ctctttggca gggtgtgtcc cagtcaaggt caagatctgc tgggagatgg 4921 gtggagtccc aagagagtta ctcttccctg gcagcttcct tggcagcaat ggt
Primer binding sites are underlined and the sequencing primer is highlighted; the mutated nucleotide is shown in red text.
1. McKenna, N. J., Xu, J., Nawaz, Z., Tsai, S. Y., Tsai, M. J., and O'Malley, B. W. (1999) Nuclear Receptor Coactivators: Multiple Enzymes, Multiple Complexes, Multiple Functions. J Steroid Biochem Mol Biol. 69, 3-12.
2. Jetten, A. M., Kurebayashi, S., and Ueda, E. (2001) The ROR Nuclear Orphan Receptor Subfamily: Critical Regulators of Multiple Biological Processes. Prog Nucleic Acid Res Mol Biol. 69, 205-247.
3. He, Y. W. (2002) Orphan Nuclear Receptors in T Lymphocyte Development. J Leukoc Biol. 72, 440-446.
4. Jetten, A. M. (2009) Retinoid-Related Orphan Receptors (RORs): Critical Roles in Development, Immunity, Circadian Rhythm, and Cellular Metabolism. Nucl Recept Signal. 7, e003.
5. Giguere, V., Tini, M., Flock, G., Ong, E., Evans, R. M., and Otulakowski, G. (1994) Isoform-Specific Amino-Terminal Domains Dictate DNA-Binding Properties of ROR Alpha, a Novel Family of Orphan Hormone Nuclear Receptors. Genes Dev. 8, 538-553.
6. Medvedev, A., Yan, Z. H., Hirose, T., Giguere, V., and Jetten, A. M. (1996) Cloning of a cDNA Encoding the Murine Orphan Receptor RZR/ROR Gamma and Characterization of its Response Element. Gene. 181, 199-206.
7. Wang, Y., Kumar, N., Solt, L. A., Richardson, T. I., Helvering, L. M., Crumbley, C., Garcia-Ordonez, R. D., Stayrook, K. R., Zhang, X., Novick, S., Chalmers, M. J., Griffin, P. R., and Burris, T. P. (2010) Modulation of Retinoic Acid Receptor-Related Orphan Receptor Alpha and Gamma Activity by 7-Oxygenated Sterol Ligands. J Biol Chem. 285, 5013-5025.
8. Jin, L., Martynowski, D., Zheng, S., Wada, T., Xie, W., and Li, Y. (2010) Structural Basis for Hydroxycholesterols as Natural Ligands of Orphan Nuclear Receptor RORgamma. Mol Endocrinol. 24, 923-929.
9. He, Y. W., Deftos, M. L., Ojala, E. W., and Bevan, M. J. (1998) RORgamma t, a Novel Isoform of an Orphan Receptor, Negatively Regulates Fas Ligand Expression and IL-2 Production in T Cells. Immunity. 9, 797-806.
10. Hirose, T., Smith, R. J., and Jetten, A. M. (1994) ROR Gamma: The Third Member of ROR/RZR Orphan Receptor Subfamily that is Highly Expressed in Skeletal Muscle. Biochem Biophys Res Commun. 205, 1976-1983.
11. Ortiz, M. A., Piedrafita, F. J., Pfahl, M., and Maki, R. (1995) TOR: A New Orphan Receptor Expressed in the Thymus that can Modulate Retinoid and Thyroid Hormone Signals. Mol Endocrinol. 9, 1679-1691.
12. Eberl, G., Marmon, S., Sunshine, M. J., Rennert, P. D., Choi, Y., and Littman, D. R. (2004) An Essential Function for the Nuclear Receptor RORgamma(t) in the Generation of Fetal Lymphoid Tissue Inducer Cells. Nat Immunol. 5, 64-73.
13. Villey, I., de Chasseval, R., and de Villartay, J. P. (1999) RORgammaT, a Thymus-Specific Isoform of the Orphan Nuclear Receptor RORgamma / TOR, is Up-Regulated by Signaling through the Pre-T Cell Receptor and Binds to the TEA Promoter. Eur J Immunol. 29, 4072-4080.
14. Dzhagalov, I., Zhang, N., and He, Y. W. (2004) The Roles of Orphan Nuclear Receptors in the Development and Function of the Immune System. Cell Mol Immunol. 1, 401-407.
15. Winoto, A., and Littman, D. R. (2002) Nuclear Hormone Receptors in T Lymphocytes. Cell. 109 Suppl, S57-66.
16. Mongrain, V., Ruan, X., Dardente, H., Fortier, E. E., and Cermakian, N. (2008) Clock-Dependent and Independent Transcriptional Control of the Two Isoforms from the Mouse Rorgamma Gene. Genes Cells. 13, 1197-1210.
17. Yang, X., Downes, M., Yu, R. T., Bookout, A. L., He, W., Straume, M., Mangelsdorf, D. J., and Evans, R. M. (2006) Nuclear Receptor Expression Links the Circadian Clock to Metabolism. Cell. 126, 801-810.
18. Takeda, Y., Kang, H. S., Angers, M., and Jetten, A. M. (2011) Retinoic Acid-Related Orphan Receptor Gamma Directly Regulates Neuronal PAS Domain Protein 2 Transcription in Vivo. Nucleic Acids Res. 39, 4769-4782.
19. Takeda, Y., Jothi, R., Birault, V., and Jetten, A. M. (2012) RORgamma Directly Regulates the Circadian Expression of Clock Genes and Downstream Targets in Vivo. Nucleic Acids Res. 40, 8519-8535.
20. Eberl, G., and Littman, D. R. (2003) The Role of the Nuclear Hormone Receptor RORgammat in the Development of Lymph Nodes and Peyer's Patches. Immunol Rev. 195, 81-90.
21. He, Y. W., Beers, C., Deftos, M. L., Ojala, E. W., Forbush, K. A., and Bevan, M. J. (2000) Down-Regulation of the Orphan Nuclear Receptor ROR Gamma t is Essential for T Lymphocyte Maturation. J Immunol. 164, 5668-5674.
22. Crellin, N. K., Trifari, S., Kaplan, C. D., Cupedo, T., and Spits, H. (2010) Human NKp44+IL-22+ Cells and LTi-Like Cells Constitute a Stable RORC+ Lineage Distinct from Conventional Natural Killer Cells. J Exp Med. 207, 281-290.
23. Ruan, Q., Kameswaran, V., Zhang, Y., Zheng, S., Sun, J., Wang, J., DeVirgiliis, J., Liou, H. C., Beg, A. A., and Chen, Y. H. (2011) The Th17 Immune Response is Controlled by the Rel-RORgamma-RORgamma T Transcriptional Axis. J Exp Med. 208, 2321-2333.
24. Roark, C. L., Simonian, P. L., Fontenot, A. P., Born, W. K., and O'Brien, R. L. (2008) Gammadelta T Cells: An Important Source of IL-17. Curr Opin Immunol. 20, 353-357.
25. Tsun, A., Chen, Z., and Li, B. (2011) Romance of the Three Kingdoms: RORgammat Allies with HIF1alpha Against FoxP3 in Regulating T Cell Metabolism and Differentiation. Protein Cell. 2, 778-781.
26. Sanos, S. L., Bui, V. L., Mortha, A., Oberle, K., Heners, C., Johner, C., and Diefenbach, A. (2009) RORgammat and Commensal Microflora are Required for the Differentiation of Mucosal Interleukin 22-Producing NKp46+ Cells. Nat Immunol. 10, 83-91.
27. Luci, C., Reynders, A., Ivanov, I. I., Cognet, C., Chiche, L., Chasson, L., Hardwigsen, J., Anguiano, E., Banchereau, J., Chaussabel, D., Dalod, M., Littman, D. R., Vivier, E., and Tomasello, E. (2009) Influence of the Transcription Factor RORgammat on the Development of NKp46+ Cell Populations in Gut and Skin. Nat Immunol. 10, 75-82.
28. He, Y. W. (2000) The Role of Orphan Nuclear Receptor in Thymocyte Differentiation and Lymphoid Organ Development. Immunol Res. 22, 71-82.
29. Raichur, S., Lau, P., Staels, B., and Muscat, G. E. (2007) Retinoid-Related Orphan Receptor Gamma Regulates several Genes that Control Metabolism in Skeletal Muscle Cells: Links to Modulation of Reactive Oxygen Species Production. J Mol Endocrinol. 39, 29-44.
30. Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schutz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., and Evans, R. M. (1995) The Nuclear Receptor Superfamily: The Second Decade. Cell. 83, 835-839.
31. Sun, Z., Unutmaz, D., Zou, Y. R., Sunshine, M. J., Pierani, A., Brenner-Morton, S., Mebius, R. E., and Littman, D. R. (2000) Requirement for RORgamma in Thymocyte Survival and Lymphoid Organ Development. Science. 288, 2369-2373.
32. Kurebayashi, S., Ueda, E., Sakaue, M., Patel, D. D., Medvedev, A., Zhang, F., and Jetten, A. M. (2000) Retinoid-Related Orphan Receptor Gamma (RORgamma) is Essential for Lymphoid Organogenesis and Controls Apoptosis during Thymopoiesis. Proc Natl Acad Sci U S A. 97, 10132-10137.
33. Xie, H., Sadim, M. S., and Sun, Z. (2005) RORgammat Recruits Steroid Receptor Coactivators to Ensure Thymocyte Survival. J Immunol. 175, 3800-3809.
34. Ma, A., Pena, J. C., Chang, B., Margosian, E., Davidson, L., Alt, F. W., and Thompson, C. B. (1995) Bclx Regulates the Survival of Double-Positive Thymocytes. Proc Natl Acad Sci U S A. 92, 4763-4767.
35. Wang, R., Xie, H., Huang, Z., Ma, J., Fang, X., Ding, Y., and Sun, Z. (2011) T Cell Factor 1 Regulates Thymocyte Survival Via a RORgammat-Dependent Pathway. J Immunol. 187, 5964-5973.
36. Guo, J., Hawwari, A., Li, H., Sun, Z., Mahanta, S. K., Littman, D. R., Krangel, M. S., and He, Y. W. (2002) Regulation of the TCRalpha Repertoire by the Survival Window of CD4(+)CD8(+) Thymocytes. Nat Immunol. 3, 469-476.
37. Krangel, M. S., Hernandez-Munain, C., Lauzurica, P., McMurry, M., Roberts, J. L., and Zhong, X. P. (1998) Developmental Regulation of V(D)J Recombination at the TCR alpha/delta Locus. Immunol Rev. 165, 131-147.
38. Littman, D. R., Sun, Z., Unutmaz, D., Sunshine, M. J., Petrie, H. T., and Zou, Y. R. (1999) Role of the Nuclear Hormone Receptor ROR Gamma in Transcriptional Regulation, Thymocyte Survival, and Lymphoid Organogenesis. Cold Spring Harb Symp Quant Biol. 64, 373-381.
39. Latinis, K. M., Norian, L. A., Eliason, S. L., and Koretzky, G. A. (1997) Two NFAT Transcription Factor Binding Sites Participate in the Regulation of CD95 (Fas) Ligand Expression in Activated Human T Cells. J Biol Chem. 272, 31427-31434.
40. Kontgen, F., Grumont, R. J., Strasser, A., Metcalf, D., Li, R., Tarlinton, D., and Gerondakis, S. (1995) Mice Lacking the c-Rel Proto-Oncogene Exhibit Defects in Lymphocyte Proliferation, Humoral Immunity, and Interleukin-2 Expression. Genes Dev. 9, 1965-1977.
41. Chen, Z., Lin, F., Gao, Y., Li, Z., Zhang, J., Xing, Y., Deng, Z., Yao, Z., Tsun, A., and Li, B. (2011) FOXP3 and RORgammat: Transcriptional Regulation of Treg and Th17. Int Immunopharmacol. 11, 536-542.
42. Chung, Y., Yang, X., Chang, S. H., Ma, L., Tian, Q., and Dong, C. (2006) Expression and Regulation of IL-22 in the IL-17-Producing CD4+ T Lymphocytes. Cell Res. 16, 902-907.
43. Liang, S. C., Tan, X. Y., Luxenberg, D. P., Karim, R., Dunussi-Joannopoulos, K., Collins, M., and Fouser, L. A. (2006) Interleukin (IL)-22 and IL-17 are Coexpressed by Th17 Cells and Cooperatively Enhance Expression of Antimicrobial Peptides. J Exp Med. 203, 2271-2279.
44. Korn, T., Bettelli, E., Oukka, M., and Kuchroo, V. K. (2009) IL-17 and Th17 Cells. Annu Rev Immunol. 27, 485-517.
45. Michel, M. L., Mendes-da-Cruz, D., Keller, A. C., Lochner, M., Schneider, E., Dy, M., Eberl, G., and Leite-de-Moraes, M. C. (2008) Critical Role of ROR-Gammat in a New Thymic Pathway Leading to IL-17-Producing Invariant NKT Cell Differentiation. Proc Natl Acad Sci U S A. 105, 19845-19850.
46. Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L., and Kuchroo, V. K. (2006) Reciprocal Developmental Pathways for the Generation of Pathogenic Effector TH17 and Regulatory T Cells. Nature. 441, 235-238.
47. Mangan, P. R., Harrington, L. E., O'Quinn, D. B., Helms, W. S., Bullard, D. C., Elson, C. O., Hatton, R. D., Wahl, S. M., Schoeb, T. R., and Weaver, C. T. (2006) Transforming Growth Factor-Beta Induces Development of the T(H)17 Lineage. Nature. 441, 231-234.
48. Ivanov, I. I., Zhou, L., and Littman, D. R. (2007) Transcriptional Regulation of Th17 Cell Differentiation. Semin Immunol. 19, 409-417.
49. Manel, N., Unutmaz, D., and Littman, D. R. (2008) The Differentiation of Human T(H)-17 Cells Requires Transforming Growth Factor-Beta and Induction of the Nuclear Receptor RORgammat. Nat Immunol. 9, 641-649.
50. Steinmetz, O. M., Summers, S. A., Gan, P. Y., Semple, T., Holdsworth, S. R., and Kitching, A. R. (2011) The Th17-Defining Transcription Factor RORgammat Promotes Glomerulonephritis. J Am Soc Nephrol. 22, 472-483.
51. Ivanov, I. I., McKenzie, B. S., Zhou, L., Tadokoro, C. E., Lepelley, A., Lafaille, J. J., Cua, D. J., and Littman, D. R. (2006) The Orphan Nuclear Receptor RORgammat Directs the Differentiation Program of Proinflammatory IL-17+ T Helper Cells. Cell. 126, 1121-1133.
52. Yang, X. O., Pappu, B. P., Nurieva, R., Akimzhanov, A., Kang, H. S., Chung, Y., Ma, L., Shah, B., Panopoulos, A. D., Schluns, K. S., Watowich, S. S., Tian, Q., Jetten, A. M., and Dong, C. (2008) T Helper 17 Lineage Differentiation is Programmed by Orphan Nuclear Receptors ROR Alpha and ROR Gamma. Immunity. 28, 29-39.
53. Ono, M., Yaguchi, H., Ohkura, N., Kitabayashi, I., Nagamura, Y., Nomura, T., Miyachi, Y., Tsukada, T., and Sakaguchi, S. (2007) Foxp3 Controls Regulatory T-Cell Function by Interacting with AML1/Runx1. Nature. 446, 685-689.
54. Dang, E. V., Barbi, J., Yang, H. Y., Jinasena, D., Yu, H., Zheng, Y., Bordman, Z., Fu, J., Kim, Y., Yen, H. R., Luo, W., Zeller, K., Shimoda, L., Topalian, S. L., Semenza, G. L., Dang, C. V., Pardoll, D. M., and Pan, F. (2011) Control of T(H)17/T(Reg) Balance by Hypoxia-Inducible Factor 1. Cell. 146, 772-784.
55. Ichiyama, K., Yoshida, H., Wakabayashi, Y., Chinen, T., Saeki, K., Nakaya, M., Takaesu, G., Hori, S., Yoshimura, A., and Kobayashi, T. (2008) Foxp3 Inhibits RORgammat-Mediated IL-17A mRNA Transcription through Direct Interaction with RORgammat. J Biol Chem. 283, 17003-17008.
56. Zhang, N., Guo, J., and He, Y. W. (2003) Lymphocyte Accumulation in the Spleen of Retinoic Acid Receptor-Related Orphan Receptor Gamma-Deficient Mice. J Immunol. 171, 1667-1675.
57. Kang, H. S., Angers, M., Beak, J. Y., Wu, X., Gimble, J. M., Wada, T., Xie, W., Collins, J. B., Grissom, S. F., and Jetten, A. M. (2007) Gene Expression Profiling Reveals a Regulatory Role for ROR Alpha and ROR Gamma in Phase I and Phase II Metabolism. Physiol Genomics. 31, 281-294.
58. Meissburger, B., Ukropec, J., Roeder, E., Beaton, N., Geiger, M., Teupser, D., Civan, B., Langhans, W., Nawroth, P. P., Gasperikova, D., Rudofsky, G., and Wolfrum, C. (2011) Adipogenesis and Insulin Sensitivity in Obesity are Regulated by Retinoid-Related Orphan Receptor Gamma. EMBO Mol Med. 3, 637-651.
59. Barendse, W., Bunch, R. J., Kijas, J. W., and Thomas, M. B. (2007) The Effect of Genetic Variation of the Retinoic Acid Receptor-Related Orphan Receptor C Gene on Fatness in Cattle. Genetics. 175, 843-853.
|Science Writers||Anne Murray|
|Authors||Ming Zeng, Kuan-Wen Wang, Bruce Beutler|